First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $43.6 million and contract revenues from collaborations of $9.8 ...

Total Revenues in the first quarter of 2025 reached $132.8 million, compared to $36.9 million in the same period last year, representing a 260% ...

First Quarter 2025 Financial Results Collaboration revenue for the three months ended March 31, 2025 increased by $18.6 million as compared to the three months ended March 31, 2024, primarily as a ...

Benchmark indices close with marginal gains after volatile session; geopolitical tensions impact markets, broader indices ...

The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall ...

Gates Foundation supports Evotec with a $ 2.5 M grant to generate critical data supporting development of next generation tuberculosis drug combinations.The collaboration continues a successful partne ...

The S&P 500 ceded 0.6%, as the benchmark index held above its 50-day moving average. The S&P 500 also snapped a nine-day ...

Vertex Pharmaceuticals (VRTX) and Neurocrine Biosciences (NBIX) shares are moving sharply after their respective earnings ...

Vertex has recorded some 25,000 prescriptions for Journavx since its January approval and is in the process of getting big ...

Sure, stocks may not have hit their ultimate bottom just yet. They're arguably closer to it than not, though. And five years ...

Detailed price information for Boston Scientific Corp (BSX-N) from The Globe and Mail including charting and trades.

BioCryst Pharma's ORLADEYO leads HAE market growth, with strong financial performance and potential despite rising ...